Trial · NCT04180163
Results by group157
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 157
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 182 | Lanadelumab 300 mg q2w or q4w | 5 | Participants | ||
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182 | 92 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364 | 189 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 182 | 55 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 364 | 152 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks Requiring Acute Treatment During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182 | 79 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks Requiring Acute Treatment During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364 | 168 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks Requiring Acute Treatment During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 182 | 46 | HAE attacks | |
| Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks Requiring Acute Treatment During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 364 | 135 | HAE attacks | |
| Number of Moderate or Severe Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182 | 72 | HAE attacks | |
| Number of Moderate or Severe Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364 | 153 | HAE attacks | |
| Number of Moderate or Severe Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 182 | 41 | HAE attacks | |
| Number of Moderate or Severe Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 70 Through Day 364 | 122 | HAE attacks | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182: No Attack | 5 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182: Mild | 2 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182: Moderate | 4 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 182: Severe | 1 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364: No Attack | 2 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364: Mild | 1 | Participants | |
| Number of Participants With Maximum Hereditary Angioedema (HAE) Attack Severity During Each of the Efficacy Evaluation Periods | Lanadelumab 300 mg q2w or q4w | Day 0 Through Day 364: Moderate | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04180163/results